A population-based, retrospective, cohort study of esophageal cancer missed at endoscopy

Chadwick, Georgina; Groene, Oliver; Hoare, Jonathan; Hardwick, Richard; Riley, Stuart; Crosby, Tom; Hanna, George B.; Cromwell, David

doi:10.1055/s-0034-1365646

Cited by 51 publications

(59 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even if properly adhered to, significant pathology can be missed; 40% of resections undertaken for presumed high grade dysplasia had an occult malignancy detected during histological analysis which had not been identified on the preoperative diagnostic endoscopy [8,9]. Additional studies indicate that 34% of early stage oesophageal cancers (both squamous and adenocarcinoma) had not been recognised in preceding endoscopies [10].…”

Section: Dysplasiamentioning

confidence: 99%

Detection of dysplasia in Barrett’s oesophagus: Are there impending optical and spectroscopic solutions?

Upchurch¹,

Old²,

Gr³

et al. 2016

Gastroenterol Hepatol Endosc

View full text Add to dashboard Cite

The incidence of Barrett's oesophagus and oesophageal adenocarcinoma is increasing in Western countries. The outcome for patients with oesophageal cancer is extremely poor with only 15.1% of patients surviving for 5 years. The dismal outcome is largely due to late diagnosis which eliminates many patients from effective treatment.Oesophageal adenocarcinoma is often preceded by the development of dysplasia in a segment of Barrett's oesophagus. With the current surveillance strategies, it is extremely difficult to not only visualise areas of dysplasia, but also to accurately identify their morphological and architectural changes during histopathological diagnosis. Consensus statements recommend mucosal resection for dysplastic change in the oesophagus, thereby, preventing the development of adenocarcinoma. This strategy requires improved diagnostic tools that can reliably distinguish patients with dysplasia.Years of research have looked at a variety of different modalities that may aid with the current dilemma of difficulties in diagnosing dysplasia. This review looks at the modalities under development and analyses their advantages and the part they may well play in the future. It also looks at the future avenues that could be explored to aid in the understanding of the disease and to improve the outcomes.

show abstract

Section: Dysplasiamentioning

confidence: 99%

Detection of dysplasia in Barrett’s oesophagus: Are there impending optical and spectroscopic solutions?

Upchurch¹,

Old²,

Gr³

et al. 2016

Gastroenterol Hepatol Endosc

View full text Add to dashboard Cite

show abstract

“…[78] Nonetheless, there is a reported 7.8% inaccuracy rate of endoscopy missing esophageal cancer during endoscopy. [9] Thus, no routine endoscopic surveillance strategy has been established for esophageal cancer.…”

Section: Screening Esophageal Cancermentioning

confidence: 99%

Esophageal cancer: Recent advances in screening, targeted therapy, and management

Gaur¹,

Kim²,

Dunkin³

2014

J Carcinog

View full text Add to dashboard Cite

The incidence of esophageal cancer remains on the rise worldwide and despite aggressive research in the field of gastrointestinal oncology, the survival remains poor. Much remains to be defined in esophageal cancer, including the development of an effective screening tool, identifying a good tumor marker for surveillance purposes, ways to target esophageal cancer stem cells as well as circulating tumor cells, and developing minimally invasive protocols to treat early-stage disease. The goal of this chapter is to highlight some of the recent advances and ongoing research in the field of esophageal cancer.

show abstract

“…Upper GI cancer miss rates are reported to be approximately 5-13%. 1,4 It is accepted that a cancer detected within three years following an endoscopy is considered to be a 'potential miss' and if detected within one year after an endoscopy is likely to be a 'definite miss'. 4,5 In view of public health campaigns to detect cancer at an earlier stage we sought to review missed cancers in our trust over a four-year period.…”

Section: Introductionmentioning

confidence: 99%

Upper gastrointestinal cancer misses: could we do better?

Ardakani

Mann

2015

Clinical Medicine

View full text Add to dashboard Cite

A population-based, retrospective, cohort study of esophageal cancer missed at endoscopy

Cited by 51 publications

References 21 publications

Detection of dysplasia in Barrett’s oesophagus: Are there impending optical and spectroscopic solutions?

Detection of dysplasia in Barrett’s oesophagus: Are there impending optical and spectroscopic solutions?

Esophageal cancer: Recent advances in screening, targeted therapy, and management

Upper gastrointestinal cancer misses: could we do better?

Contact Info

Product

Resources

About